-
Something wrong with this record ?
Plasma miR-151-3p as a Candidate Diagnostic Biomarker for Head and Neck Cancer: A Cross-sectional Study within the INHANCE Consortium
R. Pastorino, M. Sassano, F. Danilo Tiziano, L. Giraldi, R. Amore, D. Arzani, E. Abiusi, W. Ahrens, LA. Vilches, C. Canova, CM. Healy, I. Holcatova, P. Lagiou, J. Polesel, M. Popovic, S. Nygård, G. Cadoni, A. Znaor, P. Boffetta, K. Matsuo, I....
Language English Country United States
Document type Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 1991 to 1 year ago
Freely Accessible Science Journals
from 1991 to 12 months ago
Open Access Digital Library
from 1991-11-01
Open Access Digital Library
from 1991-11-01
- MeSH
- Circulating MicroRNA * MeSH
- Humans MeSH
- MicroRNAs * genetics MeSH
- Biomarkers, Tumor genetics MeSH
- Head and Neck Neoplasms * diagnosis genetics MeSH
- Cross-Sectional Studies MeSH
- Gene Expression Profiling MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Identification of screening tests for the detection of head and neck cancer (HNC) at an early stage is an important strategy to improving prognosis. Our objective was to identify plasma circulating miRNAs for the diagnosis of HNC (oral and laryngeal subsites), within a multicenter International Head and Neck Cancer Epidemiology consortium. METHODS: A high-throughput screening phase with 754 miRNAs was performed in plasma samples of 88 cases and 88 controls, followed by a validation phase of the differentially expressed miRNAs, identified in the screening, in samples of 396 cases and 396 controls. Comparison of the fold changes (FC) was carried out using the Wilcoxon rank-sum test and the Dunn multiple comparison test. RESULTS: We identified miR-151-3p (FC = 1.73, P = 0.007) as differentially expressed miRNAs in the screening and validation phase. The miR-151-3p was the only overexpressed miRNA in validation sample of patients with HNC with early stage at diagnosis (FC = 1.81, P = 0.008) and it was confirmed upregulated both in smoker early-stage cases (FC = 3.52, P = 0.024) and in nonsmoker early-stage cases (FC = 1.60, P = 0.025) compared with controls. CONCLUSIONS: We identified miR-151-3p as an early marker of HNC. This miRNA was the only upregulated in patients at early stages of the disease, independently of the smoking status. IMPACT: The prognosis for HNC is still poor. The discovery of a new diagnostic biomarker could lead to an earlier tumor discovery and therefore to an improvement in patient prognosis.
Cancer Epidemiology Unit Centro di Riferimento Oncologico Aviano IRCCS Aviano Italia
Cancer Epidemiology Unit Department of Medical Sciences Università di Torino Torino Italia
Cancer Registry of Norway Oslo Norway
Consortium for Biomedical Research in Epidemiology and Public Health Madrid Spain
Department of Medical and Surgical Sciences University of Bologna Bologna Italy
Division of Cancer Epidemiology and Prevention Aichi Cancer Center Nagoya Japan
Division of Cancer Epidemiology Nagoya University Graduate School of Medicine Nagoya Japan
International Agency for Research on Cancer World Health Organization Lyon France
Stony Brook Cancer Center Stony Brook University Stony Brook New York
Trinity College Dublin School of Dental Science Dublin Ireland
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032249
- 003
- CZ-PrNML
- 005
- 20230131151213.0
- 007
- ta
- 008
- 230120s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1158/1055-9965.EPI-22-0376 $2 doi
- 035 __
- $a (PubMed)36126276
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Pastorino, Roberta $u Department of Woman and Child Health and Public Health-Public Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia $u Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Roma, Italia $1 https://orcid.org/0000000150130733
- 245 10
- $a Plasma miR-151-3p as a Candidate Diagnostic Biomarker for Head and Neck Cancer: A Cross-sectional Study within the INHANCE Consortium / $c R. Pastorino, M. Sassano, F. Danilo Tiziano, L. Giraldi, R. Amore, D. Arzani, E. Abiusi, W. Ahrens, LA. Vilches, C. Canova, CM. Healy, I. Holcatova, P. Lagiou, J. Polesel, M. Popovic, S. Nygård, G. Cadoni, A. Znaor, P. Boffetta, K. Matsuo, I. Oze, P. Brennan, S. Boccia
- 520 9_
- $a BACKGROUND: Identification of screening tests for the detection of head and neck cancer (HNC) at an early stage is an important strategy to improving prognosis. Our objective was to identify plasma circulating miRNAs for the diagnosis of HNC (oral and laryngeal subsites), within a multicenter International Head and Neck Cancer Epidemiology consortium. METHODS: A high-throughput screening phase with 754 miRNAs was performed in plasma samples of 88 cases and 88 controls, followed by a validation phase of the differentially expressed miRNAs, identified in the screening, in samples of 396 cases and 396 controls. Comparison of the fold changes (FC) was carried out using the Wilcoxon rank-sum test and the Dunn multiple comparison test. RESULTS: We identified miR-151-3p (FC = 1.73, P = 0.007) as differentially expressed miRNAs in the screening and validation phase. The miR-151-3p was the only overexpressed miRNA in validation sample of patients with HNC with early stage at diagnosis (FC = 1.81, P = 0.008) and it was confirmed upregulated both in smoker early-stage cases (FC = 3.52, P = 0.024) and in nonsmoker early-stage cases (FC = 1.60, P = 0.025) compared with controls. CONCLUSIONS: We identified miR-151-3p as an early marker of HNC. This miRNA was the only upregulated in patients at early stages of the disease, independently of the smoking status. IMPACT: The prognosis for HNC is still poor. The discovery of a new diagnostic biomarker could lead to an earlier tumor discovery and therefore to an improvement in patient prognosis.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 650 12
- $a cirkulující mikroRNA $7 D000074166
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a stanovení celkové genové exprese $7 D020869
- 650 12
- $a nádory hlavy a krku $x diagnóza $x genetika $7 D006258
- 650 12
- $a mikro RNA $x genetika $7 D035683
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Sassano, Michele $u Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Roma, Italia $u Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy $1 https://orcid.org/0000000231581827
- 700 1_
- $a Danilo Tiziano, Francesco $u Department of Life Sciences and Public Health, Section of Genomic Medicine, Università Cattolica del Sacro Cuore, Roma, Italia $u Unit of Medical Genetics, Department of Laboratory Science and Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia $1 https://orcid.org/0000000255456158
- 700 1_
- $a Giraldi, Luca $u Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Roma, Italia $1 https://orcid.org/0000000347752042
- 700 1_
- $a Amore, Rosarita $u Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Roma, Italia $1 https://orcid.org/0000000340701496
- 700 1_
- $a Arzani, Dario $u Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Roma, Italia $1 https://orcid.org/0000000165258078
- 700 1_
- $a Abiusi, Emanuela $u Department of Life Sciences and Public Health, Section of Genomic Medicine, Università Cattolica del Sacro Cuore, Roma, Italia $u Unit of Medical Genetics, Department of Laboratory Science and Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia $1 https://orcid.org/000000019028012X
- 700 1_
- $a Ahrens, Wolfgang $u Leibniz Institute for Prevention Research and Epidemiology, BIPS, and University of Bremen, Faculty of Mathematics and Computer Science, Institute of Statistics, Bremen, Germany $1 https://orcid.org/000000033777570X
- 700 1_
- $a Vilches, Laia Alemany $u Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain $u Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain $1 https://orcid.org/0000000309456015
- 700 1_
- $a Canova, Cristina $u Department of Cardiac Thoracic Vascular Sciences and Public Health, Università di Padova, Padova, Italia $1 https://orcid.org/0000000170277935
- 700 1_
- $a Healy, Claire Mary $u Trinity College Dublin School of Dental Science, Dublin, Ireland $1 https://orcid.org/0000000305836360
- 700 1_
- $a Holcatova, Ivana $u Institute of Hygiene & Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000213660337
- 700 1_
- $a Lagiou, Pagona $u Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece $1 https://orcid.org/0000000178776253
- 700 1_
- $a Polesel, Jerry $u Cancer Epidemiology Unit, Centro di Riferimento Oncologico (CRO) Aviano, IRCCS, Aviano, Italia $1 https://orcid.org/0000000193811520
- 700 1_
- $a Popovic, Maja $u Cancer Epidemiology Unit, Department of Medical Sciences, Università di Torino, Torino, Italia $1 https://orcid.org/0000000345006572
- 700 1_
- $a Nygård, Ståle $u Cancer Registry of Norway, Oslo, Norway $1 https://orcid.org/0000000252634748
- 700 1_
- $a Cadoni, Gabriella $u Dipartimento Scienze dell'Invecchiamento, Neurologiche, Ortopediche e della Testa-Collo, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia $u Dipartimento Patologia Testa Collo e Organi di Senso, Facoltà Medicina e Chirurgia Università Cattolica Sacro Cuore, Roma, Italia $1 https://orcid.org/000000026239838X
- 700 1_
- $a Znaor, Ariana $u International Agency for Research on Cancer, World Health Organization, Lyon, France $1 https://orcid.org/0000000258494782
- 700 1_
- $a Boffetta, Paolo $u Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy $u Stony Brook Cancer Center, Stony Brook University, Stony Brook, New York $1 https://orcid.org/0000000238112791
- 700 1_
- $a Matsuo, Keitaro $u Division of Cancer Epidemiology and Prevention, Aichi Cancer Center, Nagoya, Japan $u Division of Cancer Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan $1 https://orcid.org/0000000317616314
- 700 1_
- $a Oze, Isao $u Division of Cancer Epidemiology and Prevention, Aichi Cancer Center, Nagoya, Japan $1 https://orcid.org/0000000207621147
- 700 1_
- $a Brennan, Paul $u International Agency for Research on Cancer, World Health Organization, Lyon, France $1 https://orcid.org/0000000205188714
- 700 1_
- $a Boccia, Stefania $u Department of Woman and Child Health and Public Health-Public Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia $u Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Roma, Italia $1 https://orcid.org/000000021864749X
- 773 0_
- $w MED00006442 $t Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology $x 1538-7755 $g Roč. 31, č. 12 (2022), s. 2237-2243
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36126276 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151209 $b ABA008
- 999 __
- $a ok $b bmc $g 1891166 $s 1183584
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 31 $c 12 $d 2237-2243 $e 2022Dec05 $i 1538-7755 $m Cancer epidemiology, biomarkers & prevention $n Cancer Epidemiol Biomarkers Prev $x MED00006442
- LZP __
- $a Pubmed-20230120
